BLTE's Chief Medical Officer Sells 10,000 Shares
Scholl Hendrik Peter sold 10,000 shares of BLTE, valued at $1.41 million, on June 16, 2026.
Key Points
- Scholl Hendrik Peter, BLTE's Chief Medical Officer, sold 10,000 shares worth $1.41 million on June 16, 2026.
- BLTE shares are currently trading at $138.19, with a robust presence from institutional investors.
- Analysts maintain a positive outlook on BLTE, with several firms reiterating buy ratings and price targets above $200.
On June 16, 2026, Scholl Hendrik Peter, the Chief Medical Officer of BLTE, sold 10,000 shares of the company. The shares were sold at an average price of $140.573, totaling around $1.41 million. This transaction was not part of a pre-planned trading program.
Other Institutional Activity in BLTE
Several institutional investors have been active in BLTE shares. Darwin Global Management, Ltd. increased its holdings by 29,708 shares, bringing its total to 3,057,412 shares valued at approximately $456.1 million. Paradigm Biocapital Advisors LP added 1,114,784 shares, ending with the same number of shares worth about $177.7 million. UBS Group AG significantly boosted its position by 639,607 shares, reaching a total of 768,359 shares valued at $122.5 million. Meanwhile, RTW Investments, LP maintained its stake with 715,332 shares worth $114.1 million.
BLTE Stock Snapshot
BLTE shares are currently trading at $138.19. The stock has seen active trading and significant institutional interest, contributing to its market dynamics. Analysts have shown optimism about BLTE's future, as reflected in their ratings and price targets.
Insider Buying and Selling at BLTE
In addition to Scholl Hendrik Peter's recent sale, Nathan Mata, the Chief Scientific Officer, has also been active. Mata sold shares on several occasions in May 2026 under a pre-planned trading program. His sales included 666 shares on May 7, and multiple transactions of 1,000 shares each from May 1 to May 6, with prices ranging from $153.21 to $155.78.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on BLTE. On May 26, 2026, Mizuho maintained its buy rating with a price target of $215. HC Wainwright & Co. reiterated its buy rating with a $200 target on May 21. Previously, on March 3, Morgan Stanley maintained a buy rating with a $201 target, while Cantor Fitzgerald set a target of $266.
About BLTE
BLTE is a company involved in the biotechnology sector, focusing on innovative medical solutions. The company is led by a team dedicated to advancing healthcare technologies. With a strong research and development pipeline, BLTE seeks to address unmet medical needs and improve patient outcomes.
Bottom Line
This insider transaction by Scholl Hendrik Peter is part of regular trading activity, reflecting individual investment decisions. Investors often monitor such insider activities to gauge management's sentiment about the company's prospects. The stock continues to attract institutional interest, and analysts are optimistic about its future potential, as evidenced by recent buy ratings and high price targets.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.